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ARTICLE
Nanoparticle anchoring targets immune agonists to
tumors enabling anti-cancer immunity without
systemic toxicity
Yuan Zhang1,2, Na Li1, Heikyung Suh1 & Darrell J. Irvine1,3,4,5,6
Immunostimulatory agents such as agonistic anti-CD137 and interleukin (IL)−2 generate
effective anti-tumor immunity but also elicit serious toxicities, hampering their clinical
application. Here we show that combination therapy with anti-CD137 and an IL-2-Fc fusion
achieves signiﬁcant initial anti-tumor activity, but also lethal immunotoxicity deriving from
stimulation of circulating leukocytes. To overcome this toxicity, we demonstrate that
anchoring IL-2 and anti-CD137 on the surface of liposomes allows these immune agonists to
rapidly accumulate in tumors while lowering systemic exposure. In multiple tumor models,
immunoliposome delivery achieves anti-tumor activity equivalent to free IL-2/anti-CD137 but
with the complete absence of systemic toxicity. Immunoliposomes stimulated tumor inﬁl-
tration by cytotoxic lymphocytes, cytokine production, and granzyme expression, demon-
strating equivalent immunostimulatory effects to the free drugs in the local tumor
microenvironment. Thus, surface-anchored particle delivery may provide a general approach
to exploit the potent stimulatory activity of immune agonists without debilitating systemic
toxicities.
DOI: 10.1038/s41467-017-02251-3 OPEN
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Immunostimulatory cytokines and antibodies are powerfulanti-tumor therapeutics. However, systemic administration ofimmune agonists, including approved drugs such as
interleukin-2 (IL-2) and interferon-α, are often accompanied by
serious toxicities that limit dosing, and thereby efﬁcacy1,2. Fur-
ther, there is a strong immunological rationale for combining
immune agonists to properly regulate immune responses—borne
out by studies demonstrating synergistic enhancement of anti-
tumor immunity with combination therapies3–6—but combina-
tions of immune agonists can also exhibit further escalated
toxicities7. Strategies are thus needed to enable immunostimula-
tory drugs to be used safely without compromising their anti-
tumor activity.
Two highly synergistic immune agonists are IL-2 and agonistic
antibodies or recombinant ligands for the co-stimulatory receptor
CD137. Interleukin (IL)−2 stimulates the proliferation and
effector function of cytotoxic T lymphocytes (CTLs) and natural
killer (NK) cells, while CD137 (4–1BB) is a T-cell co-stimulatory
receptor expressed by activated T-cells, NK cells, and a popula-
tion of dendritic cells8. The CD137 ligand (CD137L) is a member
of the tumor-necrosis factor (TNF) superfamily that binds CD137
to provide co-stimulatory signals for T-cell activation, and has
been shown to have anti-tumor effects in a number of models
when it binds to CD137 receptors to induce costimulation on T-
cells9. Combined stimulation of IL-2 and CD137 receptors with
IL-2 and anti-CD137 has been shown to enhance antigen-speciﬁc
CD8+ T-cell responses10. We previously showed that combina-
tion treatment with IL-2 and agonistic anti-CD137 elicited potent
anti-tumor immunity, but was also accompanied by severe sys-
temic toxicity unless these agonists were conﬁned to tumors by
intratumoural injection of the cytokine and antibody covalently
anchored to lipid nanoparticles, blocking their dissemination
beyond the tumor and tumor-draining lymph nodes (TDLNs)11.
However, this intratumoural treatment strategy would by deﬁ-
nition be limited to accessible lesions, and unable to provide
direct treatment of highly disseminated metastatic cancers.
In search of an approach to safely administer IL-2 and anti-
CD137 to disseminated tumors that might further be general-
izable to other combination therapies, here we test different
systemic modalities for delivery of this combination treatment,
and analyze root causes of the inﬂammatory toxicity of the
combination therapy. We identify stimulation of circulating
lymphocytes as a major source of the cytokine storm accom-
panying IL-2/anti-CD137 treatment. Together with our prior
results indicating that these immune agonists have high efﬁcacy
and safety if conﬁned to the tumor microenvironment11, these
results prompted us to test the utility of nanoparticle-IL-2/anti-
CD137 formulations designed to rapidly accumulate in tumors
while minimizing systemic exposure, through the enhanced per-
meation and retention (EPR) effect. To this end, we prepared
stealth (PEGylated) liposomes bearing surface-conjugated IL-2
and anti-CD137. Treatment with combination liposomes leads to
rapid accumulation of the immunostimulators in tumors but also
accelerates clearance from the bloodstream compared to the free
drugs. These combined features elicit potent activation of T-cell
and NK cell responses in tumors equivalent to high doses of free
IL-2/anti-CD137, while eliminating the cytokine storm and vas-
cular leak syndrome (VLS) triggered by the free cytokine/anti-
body combination. This allows repetitive dosing of the
immunoliposome forms leading to strong anti-tumor activity in
the absence of systemic toxicity.
Results
Anti-CD137/IL-2-Fc combination is effective but toxic.
We focused on the poorly immunogenic, aggressive B16F10
melanoma model to evaluate combination treatments. Systemic
administration of 20 µg IL-2 together with 100 µg anti-CD137
every 2 days for three doses had a modest impact on progression
of established B16F10 tumors, and led to no improvement in
survival (Fig. 1a, b). The efﬁcacy of IL-2 can be enhanced by
employing extended-pharmacokinetic (PK) forms of the cyto-
kine12,13, and thus we compared combination treatment by sys-
temic administration of anti-CD137 together with wild-type
murine IL-2 vs. an IL-2-Fc fusion with prolonged circulation half-
life12. (The Fc domain of this fusion protein contained a D265A
mutation to ablate Fcγ receptor binding.) Administration of anti-
CD137 and IL-2-Fc to tumor-bearing mice under the same
treatment schedule initially controlled tumor progression
(Fig. 1a), but this enhanced therapeutic response was accom-
panied by severe systemic toxicity, with rapid weight loss initiated
following the ﬁrst injection that accumulated with each
dose, leading to death following the third injection on day 14
(Fig. 1b, c). Increasing the time interval between doses of anti-
CD137 and IL-2-Fc failed to alleviate the severe toxicity of the
combination treatment, while administration of lower doses of
anti-CD137/IL-2-Fc lowered the degree of toxicity but also
reduced the efﬁcacy in slowing tumor progression (Fig. 1a–c,
Supplementary Fig. 1a–c), suggesting that anti-tumor efﬁcacy and
toxicity were linked in this systemic therapy.
Toxicity derived from circulating lymphocytes and VLS. Sys-
temic cytokine release is a common side effect of many immune
agonists in animal models and also in humans14, and we found
that anti-CD137/IL-2-Fc combination therapy triggered a dose-
dependent systemic cytokine storm, with signiﬁcant elevations of
several inﬂammatory cytokines and chemokines (Fig. 1d). T-cells
and NK cells have been implicated previously in side effects of
IL-215 and anti-CD13716 monotherapies, and thus we assessed
the involvement of these cells in the toxicity of the combination
treatment. Administration of anti-CD137 and IL-2-Fc to NOD/
scid/gamma chain mice that lack mature T-cells, B cells, and NK
cells, elicited negligible levels of systemic inﬂammatory cytokines/
chemokines (Supplementary Fig. 2a). To determine whether cir-
culating lymphocytes play an important role, tumor-bearing mice
were treated with IL-2-Fc/anti-CD137 in the presence of FTY720,
a sphingosine-1-phosphate analog that depletes both T-cells and
NK cells from the peripheral blood by blocking their egress from
lymph nodes17,18. As expected, FTY720 treatment dramatically
lowered the number of CD4+ and CD8+ T-cells in blood, and
partially reduced NK cell levels during treatment (Supplementary
Fig. 2b). FTY720-treated animals showed greatly lowered sys-
temic cytokine release in response to the combination therapy,
suggesting that sustained stimulation of circulating lymphocytes
plays an important role in the cytokine storm elicited by the
combination therapy (Fig. 1e).
To determine the relative roles of T-cells and NK cells and
evaluate cytokine/chemokine levels over time during anti-CD137/
IL-2-Fc therapy, we depleted CD8+ T-cells or NK cells from
C57Bl/6 mice bearing B16F10 tumors, then began systemic anti-
CD137/IL2-Fc therapy on day 8 after tumor inoculation
(Supplementary Fig. 3a). In animals receiving an isotype control
in lieu of depleting antibodies, the combination therapy triggered
sustained inﬂammatory cytokine/chemokine levels in serum that
either increased or were sustained from day 10 to day 13 post
tumor inoculation, while depletion of either CD8+ T-cells or NK
cells during treatment in wild-type mice greatly reduced the
cytokine storm elicited by the combination therapy at these time
points (Supplementary Fig. 3b). However, depletion of either NK
or CD8 cells during anti-CD137/IL2-Fc therapy was still
accompanied by gross weight loss in treated animals
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(Supplementary Fig. 3c), suggesting additional mechanisms of
toxicity beyond the cytokine storm produced by these lympho-
cytes. IL-2 has previously be reported to elicit vascular damage
through direct stimulation of endothelial cells or indirectly
through granulocytes15,19–21. Indeed, IL-2-Fc/anti-CD137 com-
bination therapy induced edema characteristic of VLS in the lung
1 day after the second i.v. injection (Fig. 1f). One day after three
injections, IL-2-Fc/anti-CD137 combination therapy resulted in
increased interstitial pulmonary inﬁltrates (Fig. 1g). Thus, IL-2-
Fc/anti-CD137 combination therapy induces both a systemic
cytokine release dependent on circulating T and NK cells
and VLS.
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Synthesis of anchored antibody immunoliposomes. Given the
toxicity of the systemic free drug combination, we considered
strategies to concentrate IL-2 and anti-CD137 in tumors with less
systemic exposure. We hypothesized that conjugation of these
immune agonists to nanoparticles could promote their redis-
tribution to tumors through the enhanced permeability and
retention effect, while lowering their persistence in the systemic
circulation relative to the free drugs. To test this idea, we coupled
IL-2-Fc and F(Ab′)2 fragments of anti-CD137 to PEGylated
liposomes via hinge region thiols of the two molecules. PEGylated
liposomes conjugated with isotype-matched IgG antibody were
used as controls. The resulting immunoliposomes were uni-
lamellar vesicles with sizes of 80± 22 nm and zeta potentials of
−25 mV as measured by cryogenic transmission electron micro-
scopy (cryo-TEM) and dynamic light scattering (DLS) (Fig. 2a).
From the conjugation efﬁciency, per 1 mg lipids, there were ~123
µg anti-CD137 or ~99 µg IL2-Fc conjugated on the liposome
surfaces. The small size allows better tumor penetration via the
EPR effect, while PEGylation reduces serum protein opsonization
to minimize phagocytosis by reticuloendothelial system and
premature particle clearance before reaching the target site in
tumors22. Both ﬂow cytometry and confocal imaging showed that
ﬂuorescently labeled liposome-conjugated anti-CD137 (Lipo-
αCD137) and liposome-conjugated IL-2-Fc (Lipo-IL-2-Fc) bound
at high levels to activated T-cells compared to control IgG-
conjugated liposomes (Lipo-IgG) after a 3 h incubation in vitro
(Supplementary Fig. 4a, b). Lipo-IL-2-Fc and Lipo-αCD137 sti-
mulated T-cells similarly to free IL-2-Fc and anti-CD137, as
measured by the CD8+ T-cell counts and IFN-γ secretion,
respectively, in vitro (Fig. 2b, c). These data suggest that the
conjugation of IL-2-Fc and anti-CD137 to liposome surface via
maleimide coupling did not compromise their biological activity
and binding afﬁnity to their corresponding receptors.
We further measured the liposome stability and breakdown
in vitro. IRDdye-labeled anti-CD137 or IL-2-Fc were conjugated
to liposomes carrying encapsulated Alexa Fluor-labeled ovalbu-
min as a marker of intact vesicles, and ratios of anti-CD137 or IL-
2-Fc remaining bound to liposomes in serum-containing buffer
were measured over time. Normalized to the initial time point,
both IL-2-Fc and anti-CD137 levels remained approximately
constant over two days, suggesting the immune agonists were
stably conjugated on the liposome surface over time (Supple-
mentary Fig. 5).
Liposome delivery alters therapy PK and biodistribution. We
ﬁrst compared the in vivo pharmacokinetics and biodistributions
of IL-2-Fc and anti-CD137 carried by liposomes vs. the free
molecules in mice bearing subcutaneous tumors. Liposomal anti-
CD137 exhibited a total systemic exposure (area under the curve
(AUC)) ~60% of free anti-CD137 in the blood, while Lipo-IL-2-
Fc exhibited signiﬁcantly faster clearance than IL-2-Fc, with an
AUC approximately half of the free cytokine (Fig. 2d, e, Table 1).
At 24 h, the amount of circulating Lipo-IL-2-Fc in the blood was
much lower than the amount of IL-2-Fc (Fig. 2e). We also
observed that although soluble and liposomal IL-2-Fc and anti-
CD137 exhibited similar binding to circulating NK cells at 24 h,
substantially reduced levels of Lipo-IL-2-Fc associated with
T-cells in the blood at 24 h post injection compared to IL-2-Fc
(Fig. 2j). Similar differences in binding of soluble and liposome-
bound IL-2-Fc were observed when anti-CD137 and IL-2-Fc were
administered simultaneously. Examining their biodistributions
more broadly, Lipo-IL-2-Fc exhibited higher accumulation in the
spleen and lymph nodes than IL-2-Fc, and Lipo-αCD137 had
higher kidney accumulation than anti-CD137, while accumula-
tion in other organs was largely similar for liposomal vs. free
proteins (Fig. 2f, g). Thus, the liposomal agonists cleared from the
blood more quickly than their free counterparts, with Lipo-IL-2-
Fc particularly exhibiting more rapid clearance from the blood
than soluble IL-2-Fc.
Since the strong absorption across the visible spectrum for
melanin23 made bulk ﬂuorescence-based measurement of tumor
uptake of the labeled IL-2 and anti-CD137 unreliable, an
unpigmented B16F10 Trp2 knockout (KO) cell line3 (B16F10-
Trp2KO) that does not produce melanin was used as a substitute
for B16F10 in tumor accumulation experiments for the quantita-
tion of the % injected dose that localized to the tumor. In the
B16F10-Trp2KO xenografts, after bolus i.v. injection, liposomal
anti-CD137 showed a approximately ﬁvefold increase of tumor
accumulation compared to free anti-CD137 at the 4 and 24 h time
points (Fig. 2h). Liposomal IL-2-Fc showed a ~50% increase in
tumor accumulation comparing to that of free IL-2-Fc at 4 h,
while accumulations of liposomal and free IL-2-Fc were
comparable at 24 h (Fig. 2i). We further examined the tumor
permeation of the soluble or liposomal agonists microscopically
in tissue sections. Animals bearing subcutaneous B16F10 ﬂank
tumors were administered i.v. injections of ﬂuorescently labeled
soluble proteins or protein-anchored liposomes, followed by
killing and tissue sectioning for confocal imaging of tumor
tissues. We observed striking differences in their tumor
accumulation at 1 h post administration. Liposomal immune
agonists displayed substantially greater accumulation in tumors
compared to their soluble forms (Fig. 3a, b). Quantiﬁcation of
total anti-CD137/IL-2-Fc signal in tumor sections showed at 4.5-
fold increase in uptake of the combined therapeutics in the
liposomal form compared to the free drugs (Fig. 3a, p< 0.001).
Thus, liposomes showed more rapid clearance from the blood
accompanied by enhanced tumor accumulation at early times—
indicating lower systemic exposure but retention of intratumoural
delivery of these agonists.
Immunoliposomes elicit anti-tumor efﬁcacy without toxicity.
We next evaluated the relative anti-tumor efﬁcacy and safety of
Fig. 1 Anti-CD137 and IL-2-Fc combination immunotherapy effectively arrests tumor growth, but elicits lethal in vivo toxicity. Groups of C57BL/6 mice (n=
5 mice/group) were subcutaneously inoculated with 5 × 105 B16F10 cells, and received i.v. injections of αCD137 and IL-2 or αCD137 and IL-2-Fc on days 8,
11, and 14, at a dose of 100 µg anti-CD137 and 20 µg IL-2 or 60 µg IL-2-Fc (equivalent mole dose to 20 µg IL-2). A third group received αCD137 and IL-2-Fc
only on days 8 and 15. Shown are tumor sizes (a), survival (b), and body weight (normalized to day 8) (c). d B16F10 tumor-bearing mice received i.v.
injections of αCD137 + IL-2-Fc. One and 2 days later, sera from peripheral blood were collected, and inﬂammatory cytokine and chemokine levels in sera
were measured by luminex cytokine assays. **p< 0.005, ***p< 0.0005. e Groups of C57BL/6 mice (n= 5 mice/group) were subcutaneously inoculated
with 5 × 105 B16F10 cells and were given daily i.p. injection of FTY720 starting day 7 to deplete circulating lymphocytes. Mice received i.v. injections of
αCD137 and IL-2-Fc on days 8. One day and 3 days later, sera from peripheral blood were collected and inﬂammatory cytokine/chemokine levels in sera
were measured by luminex cytokine assays. *p< 0.05, ** p< 0.005. f, gMice bearing subcutaneous melanoma received i.v. injections of αCD137 and IL-2-
Fc on days 8 and 10. One day later, lungs were collected and freshly weighed before lyophilization. The lyophilized lungs were weighed, and the water
content in the lung was calculated (f). *p< 0.05. Lymphocyte inﬁltrates in the lung were analyzed using ﬂow cytometry 1 day after the last injection (g).
*p< 0.05. All measurements shown are mean± s.e.m.
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Fig. 2 Liposome-conjugated anti-CD137 and IL-2-Fc retain bioactivity with lower systemic exposure than the free drugs. a Representative cryo-TEM image
of IL-2-Fc-liposome (anti-CD137 liposomes were qualitatively identical). b Polyclonal T-cells from C57Bl/6 mice were activated for 2 days with anti-CD3/
CD28 beads, then soluble or liposomal IL-2-Fc (10 ng/mL of protein) were added, and CD8+ and CD4+ T-cell counts were determined on days 3 and 4.
c Activated T-cells were incubated with soluble anti-CD137 or Lipo-αCD137 (ﬁnal αCD137 concentration: 10 μg/mL) for 6 h, and the secreted IFN-γ in the
cell culture supernatant was analyzed by ELISA. d–g Groups of C57Bl/6 mice were injected s.c. with 5 × 105 B16F10 tumor cells, and then received i.v.
injections of ﬂuorescently labeled soluble IL-2-Fc, soluble anti-CD137, Lipo-αCD137, or Lipo-IL-2-Fc proteins (100 µg αCD137, 60 µg IL-2-Fc) on day 10.
Pharmacokinetics of the labeled proteins were followed over time in the blood (d, e) and protein levels in the organs were compared at 4 and 24 h later
(f, g). *p< 0.05, **p< 0.005, ***p< 0.0005. h, i The anti-CD137 (h) and IL-2-Fc (i) accumulation in unpigmented B16F10-Trp2KO xenograft tumors were
determined at 4 and 24 h after bolus i.v injection. *p< 0.01, **p< 0.005. j Twenty-four hours after i.v. injections of ﬂuorescently labeled free or liposomal
αCD137 and IL-2-Fc, lymphocytes from peripheral blood were collected, and their association with ﬂuorescent protein drugs were analyzed by ﬂow
cytometry. *p< 0.05, **p< 0.01. All measurements shown are mean± s.e.m. NS not signiﬁcant
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Table 1 Pharmacokinetic parameters of the PK study
A α (per h) B β (per h) t1/2,α (h) t1/2,β (h) AUV
IL2-Fc 0.57± 0.08 3.66± 1.00 0.43± 0.08 0.05± 0.01 0.20± 0.03 13.22± 2.95 8.27± 2.40
Lipo-IL2-Fc 0.72± 0.04 2.19± 0.33 0.28± 0.04 0.09± 0.01 0.32± 0.05 7.52± 0.83 3.37± 0.26
αCD137 0.31± 0.15 3.70± 2.59 0.69± 0.15 0.02± 0.01 0.31± 0.25 44.12± 10.84 41.95± 2.68
Lipo-αCD137 0.41± 0.13 4.79± 2.36 0.59± 0.13 0.02± 0.01 0.18± 0.10 32.07± 8.51 28.09± 12.53
t1/2,α fast clearance half-life, t1/2,β slow clearance half-life, AUC area under the curve
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Fig. 4 Immunoliposome IL-2-Fc/αCD137 therapy inhibits melanoma tumor growth and prolongs survival without toxicity. a–c Groups of C57Bl/6 mice
(n= 6–7 per group) were inoculated with 5 × 105 B16F10 tumor cells s.c. on day 0, then received i.v. injections of αCD137 + IL-2-Fc, Lipo-αCD137 + Lipo-IL-
2-Fc, or Lipo-IgG on days 8, 10, 12, and 14 after tumor cell inoculation (100 μg per dose αCD137 and 60 μg per dose IL-2-Fc). Shown are mean tumor sizes
(a, *p< 0.0005 Lipo-CD137/IL-2-Fc vs. untreated and Lipo-IgG), relative body weight (b, normalized to day 8), and overall survival c vs. time. ***p< 0.001
Lipo-CD137/IL-2-Fc vs. untreated, αCD137/IL-2-Fc and Lipo-IgG. d Groups of C57Bl/6 mice (n= 4/group) were inoculated with 5 × 105 B16F10 tumor cells
s.c. on day 0, then were treated on days 8 and 10 as in a. On day 11, animals were killed and water content in the ling was measured. *p< 0.05. e Groups of
C57Bl/6 mice (n= 5/group) were inoculated with 5 × 105 B16F10 tumor cells s.c. on day 0, then were treated on days 8, 10, and 12 as in a. On days 9, 10,
and 13, sera were collected from peripheral blood and analyzed for levels of cytokines and chemokines by luminex assays. *p< 0.05, **p< 0.005,
***p< 0.0001. Shown are mean± s.e.m.
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immunoliposomes compared to the free IL-2-Fc/αCD137 com-
bination therapy. B16F10 tumor-bearing mice were administered
free or liposomal anti-CD137 and IL-2-Fc combinations four
times every other day. As shown in Fig. 4a, Lipo-αCD137/Lipo-
IL2-Fc combination therapy signiﬁcantly delayed tumor out-
growth, while isotype control liposomes (Lipo-IgG) had no
impact on tumor progression. Importantly, this halt in tumor
growth was achieved without evidence of toxicity from animal
body weights, in contrast to the free agonists, which induced
steady weight decline to animal mortality as before (Fig. 4b).
Correlating with these distinct outcomes, immunoliposome
treatment led to signiﬁcantly enhanced survival compared to
untreated tumors, while soluble anti-CD137 and IL-2-Fc treat-
ment led to reduced survival due to immunotoxicity (Fig. 4c).
One day after the second injection, mice treated with αCD137/IL-
2-Fc had a signiﬁcant elevation of serum levels of cholesterol and
the liver enzymes aspartate transaminase (AST) and alanine
transaminase (ALT), as well as elevated serum creatinine kinase,
suggesting liver and kidney damage (Supplementary Fig. 6a–d).
By contrast, Lipo-αCD137 + Lipo-IL-2-Fc elicited no changes in
any of these markers above baseline. Further, 1 day after two
injections, mice treated with Lipo-αCD137 + Lipo-IL-2-Fc
showed alleviated VLS compared to the anti-CD137 + IL-2-Fc
group, as indicated by water content in the lungs (Fig. 4d).
Immunoliposome therapy also showed no evidence of systemic
cytokine storm induction, as evidenced by levels of proin-
ﬂammatory cytokines in serum (Fig. 4e). To assess the generality
of these ﬁndings, we carried out similar studies in balb/c mice
bearing A20 B cell lymphoma tumors. Tumor growth was
effectively suppressed after the treatment with either αCD137/IL-
2-Fc or Lipo-αCD137/Lipo-IL-2-Fc (Supplementary Fig. 7a).
However, soluble αCD137/IL-2-Fc therapy led to steadily accu-
mulating weight loss and elevated levels of inﬂammatory cyto-
kines in the circulation, while the liposomal therapy elicited no
evidence of toxicity (Supplementary Fig. 7b, c). Thus, in multiple
tumor models immunoliposome therapy maintained the anti-
tumor efﬁcacy but eliminated multiple features of the systemic
toxicity elicited by free IL-2-Fc + anti-CD137 treatment.
Melanoma is an aggressive disease that is highly lethal upon
metastasis. We thus also tested the anti-tumor efﬁcacy of
immunoliposome therapy in a lung metastasis model. Six days
post i.v. injection of luciferase-expressing B16F10 cells, when
pulmonary tumor nodules could be clearly detected by biolumi-
nescence imaging, treatment was initiated. In untreated and Lipo-
IgG control groups, growth of lung tumors escalated quickly
2 weeks after tumor cell inoculation (Fig. 5a). In striking contrast,
Lipo-αCD137/IL-2-Fc therapy greatly suppressed tumor growth,
with negligible lung signal detected through ~25 days, as
monitored by IVIS bioluminescence imaging (Fig. 5a, b).
Following the third treatment on day 10, mice administered
Lipo-αCD137/IL2-Fc already showed a signiﬁcant reduction of
tumor burden in the lung comparing to control Lipo-IgG and
untreated groups (Fig. 5b, c). By contrast, soluble anti-CD137/IL-
2-Fc failed to elicit any anti-tumor effect, and all animals treated
with the soluble combination died on day 10 due to accumulated
in vivo toxicity (Fig. 5b–d). Lipo-αCD137/IL-2-Fc signiﬁcantly
suppressed tumor progression in the lung and enhanced survival
comparing to untreated and Lipo-IgG groups, with 20% of
animals achieving complete tumor eradication (Fig. 5e).
Inspired by the striking therapeutic efﬁcacy in the early
treatment model, we further assessed whether Lipo-αCD137/IL-
2-Fc was effective in treating metastases at a later stage.
Treatment with three injections of the αCD137/IL-2-Fc combina-
tion was initiated on day 14 post tumor injection, when much
larger pulmonary metastatic foci were established compared to
day 6. Free αCD137/IL-2-Fc failed to control tumor growth and
led to lethal immunotoxicity as before, but mice treated with
Lipo-αCD137/IL-2-Fc showed no signs of toxicity and had a
signiﬁcantly lower tumor burden in the lungs than all other
groups (Fig. 5f). Therefore, in the lung metastasis model, Lipo-
αCD137/IL-2-Fc therapy could eradicate tumors in a fraction of
animals when therapy was administered at an early stage and also
signiﬁcantly inhibited tumor growth in the lungs even the therapy
was initiated at later stages of tumor progression. Similar to the
results in treatment of ﬂank tumors, lethal toxicity accompanying
the soluble form of this combination therapy was eliminated by
immunoliposome delivery.
IL-2-Fc plays a dominant role in therapy toxicity. To better
understand the side effects induced by αCD137/IL-2-Fc treat-
ment, we exploited the fact that liposome delivery blocks the side
effects of this therapy to determine the relative contributions of
the two agents to the toxicity of the soluble therapy. To this end,
combination treatments were administered where one of the
agents was delivered in soluble form and one was liposome-
bound and serum cytokines and chemokines were evaluated after
a single injection. As before, soluble αCD137 + IL-2-Fc triggered
signiﬁcant elevations of IFN-γ, IL-6, MCP-1, and TNF-α
(Fig. 6a–d). Liposomal delivery of αCD137 with soluble IL-2-Fc
also induced inﬂammatory cytokines and chemokines, at levels
one-third to one-half that seen with soluble αCD137/IL-2-Fc
treatment. By contrast, Lipo-IL-2-Fc combined with soluble
αCD137 induced minimal or undetectable levels of inﬂammatory
cytokines comparable to control untreated animals, suggesting
that the bulk of the toxicity derived from the soluble combination
derives from the long half-life IL-2 molecule (Fig. 6a–d).
Liposomes induce intratumoural immune responses. Given the
effective accumulation of the immunoliposomes in tumors and
their substantial anti-tumor efﬁcacy, we hypothesized that the
immunoliposomes effectively stimulate an intratumoural immune
response despite lowering systemic exposure to the two immu-
nomodulators. To test this idea, we evaluated immunologic
changes in the tumor microenvironment following systemic anti-
CD137 and IL-2-Fc combination therapy. One day after three
injections of αCD137/IL-2-Fc therapy in tumor-bearing mice,
tumors and blood were collected and subjected to ﬂow cytometry
analysis for lymphocytes counts, cytokine production, and bio-
marker analysis (Fig. 7a). Both αCD137/IL-2-Fc and Lipo-
αCD137/Lipo-IL-2-Fc treatment induced substantial CD8+ T-cell
and NK cell tumor inﬁltrates (to comparable levels) and increased
intratumoral CD8+/Treg ratios approximately ﬁvefold
(Fig. 7b–d). We further evaluated whether T-cells in tumors,
blood and TDLNs were primed following treatment, by analyzing
IFN-γ production in response to ex vivo polyclonal re-
stimulation. We found increased numbers of IFN-γ-producing
CD8+ and CD4+ T-cells in both cohorts receiving αCD137/IL-2-
Fc compared to control Lipo-IgG and untreated groups
(Fig. 7e–g), with soluble and liposome therapy again eliciting
similar levels of T-cell activation. Additionally, we evaluated T-
cell degranulation and T-cell cytotoxicity upon ex vivo polyclonal
stimulation. Lipo-αCD137/IL-2-Fc and αCD137/IL-2-Fc induced
a two to threefold elevation of CD107 expression in CD8+ T-cells
from tumors (Fig. 7h) as well as elevated granzyme B expression
in CD8+ T-cells in TILs (Fig. 7i). Altogether these results suggest
that both soluble and liposome-delivered αCD137/IL-2-Fc ther-
apy strongly induces T-cell priming in tumors and TDLNs, and
promotes a pro-immune shift in the composition of intratumoral
leukocytes. To obtain some insight into the duration of stimula-
tion following liposome treatment, 24 h after three i.v. injections
of soluble or liposomal immunotherapy, we assayed for levels of
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Fig. 5 Immunoliposome therapy suppressed tumor progression in a lung metastatic model with low toxicity. a–e Groups of C57Bl/6 mice (n= 5 per group)
were injected on day 0 with 5 × 105 luciferase-expressing B16F10 tumor cells i.v. Animals then received i.v. injections of αCD137 + IL-2-Fc, Lipo-αCD137 +
Lipo-IL-2-Fc, or Lipo-IgG on days 6, 8, and 10 (100 μg per dose αCD137 and 60 μg per dose IL-2-Fc). a Mean total ﬂux of lung luciferase signal from mice
vs. time. b Bioluminescence images during the therapy. c Comparison of mean luciferase signals on day 10. *p< 0.05 Lipo-CD137/IL-2-Fc vs. untreated,
αCD137/IL-2-Fc and Lipo-IgG. d Mean relative body weights of animals during the therapy (normalized to day 6). e Overall survival. f Groups of C57Bl/6
mice (n= 5 per group) were injected on day 0 with 5 × 105 luciferase-expressing B16F10 tumor cells then received i.v. injections of αCD137/IL-2-Fc,
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NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02251-3 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:6 |DOI: 10.1038/s41467-017-02251-3 |www.nature.com/naturecommunications 9
phosphorylated STAT5 in intratumoural T-cells and NK cells
(a downstream product of IL-2 receptor signaling). Both soluble
and liposomal αCD137/IL-2-Fc induced intracellular pSTAT5
activation in CD8 T-cells and NK cells in both primary (Fig. 7j)
and lung metastatic (Fig. 7k) melanoma models, with the soluble
agents activating pSTAT5 in NK cells slightly more effectively
than liposomes. These results suggest that both soluble and
liposomal immune-agonist signaling persists for at least 24 h post
administration.
Discussion
Cytokines and immune-agonist antibodies, while of great interest
for cancer immunotherapy, often result in the development of
severe dose-limiting side effects, limiting their therapeutic
potential. In the case of cytokines, these side effects are in part
linked to the high doses that are often administered to com-
pensate for the very short half-lives these small proteins tend to
exhibit in the circulation. For example, high-dose (HD) IL-2
cancer immunotherapy stimulates the proliferation of cytotoxic
CD8+ T-cells and NK cells, promoting tumor regression24,25, and
it has been approved for the treatment of metastatic melanoma
and renal cancer for its anti-tumor activity26,27. However, HD
IL-2 therapy is accompanied by a systemic cytokine storm and
excessive vascular permeability known as VLS, and thus intensive
patient management is required during IL-2 therapy26. These
undesirable adverse effects are life-threatening and result in the
compromised response to immunotherapies.
These challenges have motivated a number of strategies to
improve the safety proﬁles while maintaining the therapeutic
efﬁcacy of immune agonists, particularly cytokines. Cytokines
have been molecularly engineered to alter their speciﬁcity for
receptor subunits in order to restrict their stimulation to only
certain cellular targets28, or complexed with monoclonal anti-
bodies to achieve a similar goal15. Approaches such as PEGylation
have been used to extend the half-life of cytokines in order to
allow lower cytokine dosing, but the therapeutic window of these
approaches remains narrow29,30. Targeting of the action of
cytokines to the tumor microenvironment should provide
another approach to minimize systemic toxicity from immune
agonists, and this concept has been pursued clinically in the form
of immunocytokines comprised of antibodies fused with cytokine
components31. However, systemic administration of these engi-
neered agonists often fails to achieve targeted tumor delivery, due
to the rapid binding of the cytokine component to circulating
immune cells32. Thus, novel strategies to target immune-agonist
function to tumors remain of interest.
IL-2 and agonistic anti-CD137 act in complementary pathways
to promote multiple aspects of innate and adaptive immunity
against tumors, but exhibit signiﬁcant toxicity as monotherapies
in humans and are highly toxic as a combination treatment in
mice. Use of IL-2-Fc fusions to increase the half-life of IL-2
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increase anti-tumor efﬁcacy but still induce substantial toxicity at
functional doses. We previously showed that conjugation of IL-2
and anti-CD137 to liposomes for intratumoural injection con-
trolled tumor progression without toxicity11, demonstrating that
IL-2/anti-CD137 signaling conﬁned to tumors and TDLNs is
sufﬁcient for anti-tumor efﬁcacy, suggesting that the toxicity
arising from systemic exposure to these agents is separable from
anti-tumor activity. However, strategies enabling systemic treat-
ment of disseminated metastatic disease are needed.
Here we show that an approach well-studied in the nanome-
dicine ﬁeld, using nanoparticle as a carrier to promote tumor
accumulation of these drugs, is particularly effective as an
approach for immunotherapy. Macromolecules and nanoparticles
administered systemically accumulate in tumors via the EPR
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effect, whereby leaky tumor vasculature and poor lymphatic
clearance in tumors lead to accumulation of these agents in
tumors over time33. While wild-type IL-2 has a very short half-life
precluding signiﬁcant tumor accumulation following a single
systemic administration34, extended-PK IL-2-Fc circulates long
enough to accumulate in tumors, together with the long half-life
anti-CD137 antibody. However, antibody-sized macromolecules
accumulate slowly in tumors, with peak accumulation not
occurring until ~48 h after administration35. Thus, for these free
protein drugs, it is impossible to achieve efﬁcient tumor accu-
mulation without extended systemic exposure. Contrasting to the
slow buildup of therapeutic proteins in tumors, nanoparticles in
the 50–200 nm size range show much more rapid tumor accu-
mulation; in studies where early time points have been measured,
maximal tumor accumulation has been observed as early as 4–6 h
after administration36,37. This timescale also suggests that nano-
particles with much shorter half-lives than antibodies can effec-
tively accumulate in tumors with a much lower total systemic
exposure. We covalently linked IL-2 and anti-CD137 to lipo-
somes, rather than encapsulating free forms of these drugs, to
avoid release of the free molecules, which as shown by our prior
studies of injecting soluble IL-2/anti-CD137 leads to systemic
exposure and cytokine storms even following intratumoral
injection11. By covalently linking the payloads to the liposome
surfaces, their biodistribution is dominated by the liposome
trafﬁcking and release of free cytokine/antibody is minimal.
Using PEGylated liposomes as a scaffold for delivery of
covalently anchored anti-CD137 and IL-2-Fc, we showed
that these nanocarriers modulated the pharmacokinetics
and biodistribution of the toxicity-inducing cytokines, providing
rapid accumulation in tumors with reduced systemic exposure.
Modest alterations in the systemic circulation behavior correlated
with an elimination of systemic cytokine storms, VLS, and
lethal toxicity. However, the nanoparticle forms retained the
full anti-tumor activity of the parent drug combination, and
achieved similar priming of immune cell inﬁltration and T-cell
activation within tumors as the free cytokine/antibody
combination.
A strength of the approach described here is that it should be
generalizable to diverse immunomodulatory agents including
small molecule and biologic drugs, and immunoliposomes have
already reached clinical testing in the setting of targeting che-
motherapy drugs to tumors. We demonstrate here that these
platforms, even without encapsulated drug cargos, can be very
effective when the particles carry immune agonists rather than
tumor-targeting moieties, relying on the EPR effect for a small
but effective dose of these drug to reach tumors following sys-
temic administration. While it continues to be debated how
homogeneous and effective the EPR effect is in human
patients38,39, there are several points that make us encouraged
that the data shown here in mice could predict efﬁcacy in
humans. First is the key distinction between the drug agents/
cellular targets of traditional nanomedicine—where typically
chemotherapy or targeted drugs must reach tumor cells, and must
deliver a functional dose of drug to every single tumor cell—vs.
immunotherapy, where small amounts of potent cytokines/anti-
bodies reaching a proportion of immune cells in the tumor
microenvironment may have efﬁcacy, or which may bind
immune cells in circulation that carry these agents into the tumor.
Notably, our data in a lung metastasis melanoma model
demonstrated that immunoliposomes could elicit superior ther-
apeutic efﬁcacy and survival beneﬁts for treating metastatic
lesions compared to their soluble counterparts, in both small
metastatic lesions and larger established metastatic nodules.
Second, imaging-based clinical methods (e.g., magnetic resonance
imaging imaging of iron oxide nanoparticles to identify patients
exhibiting nanoparticle accumulation in tumors prior to nano-
particle therapy), are beginning to be employed clinically40,41,
which pave the way for rational selection of patients for EPR-
dependent therapies. Lastly, a variety of clinically-relevant stra-
tegies to increase the EPR effect in tumors are beginning to be
deﬁned, such as radiation therapy42,43, photodynamic therapy44,
and use of vasodilators45, to name just a few. We hypothesize that
this approach is better suited to immunostimulatory agents that
act at low doses rather than drugs that block inhibitory receptors
(e.g., anti-PD-1, anti-CTLA-4), which may require high doses to
fully block target receptors on tumor-inﬁltrating immune cells.
Further work will be required to evaluate these issues.
Methods
Materials. Anti-CD137 (clone LOB12.3), anti-CD8a (clone 2.43), anti-NK1.1
(clone PK136), and rat IgG isotype control antibodies (clone HRPN) were from
BioXCell. Dioleoylphosphocholine (DOPC), polyethylene glycol 2000-
distearoylphosphoethanolamine (DSPE-PEG), and maleimide-PEG2000-DSPE
were obtained from Avanti Polar Lipids. Fluorescent antibodies against mouse
CD45 (1:100 dilution, cat# 17–0451–82), CD3 (1:100 dilution, cat# 48–0032–82),
CD4 (1:100 dilution, cat# 45–0042–82), NK1.1 (1:100 dilution, cat# 25–5941–81),
IFNγ (1:50 dilution, cat# 12–7311–41), CD16/32 (1:100 dilution, cat# 14–0161–82),
CD25 (1:100 dilution, cat# 45–0251–82) and Foxp3 (1:50 dilution, cat#
17–5773–82) were from eBioscience. Anti-mouse CD8a (1:100 dilution, cat#
100747), CD107a (1:100 dilution, cat# 121606), CD107b (1:100 dilution, cat#
108504), granzyme B (1:25 dilution, cat# 515406) and FOXP3 Fix/Perm buffer set
were from BioLegend. Luminex multiplex magnetic bead kits and centrifugal ﬁlter
units were obtained from EMD Millipore. Alexa ﬂuorophore dyes, Pierce F(ab′)2
preparation Kit and Dynabeads mouse T-Activator CD3/CD28 for T-cell expan-
sion and activation kits and LIVE/DEAD Fixable Aqua Dead Cell Stain kits were
purchased from Thermo Fisher Scientiﬁc. IRDye 800CW Infrared dye was from LI-
COR. Alexa Fluor 488-labeled ovalbumin (OVA) was from Invitrogen. Con-
canavalin A Type VI (Con A) and cholesterol were from Sigma-Aldrich. Recom-
binant IL-2 and IL-7 were purchased from PeproTech. EasySep Mouse CD8+ T-cell
enrichment Kit was from Stemcell. D-luciferin was from Caliper Life Sciences.
Collagenase IV and DNase were from Roche. FTY720 was purchased from Cayman
Chemical.
Immunoliposome preparation and characterization. A lipid mixture composed
of DOPC, cholesterol, DSPE-PEG, and DSPE-PEG-maleimide in a molar ratio of
Fig. 7 Anti-CD137/IL-2-Fc therapy induces intratumoural immune activation. Groups of C57Bl/6 mice (n= 5 per group) were injected on day 0 with
5 × 105 B16F10 tumor cells s.c. Animals then received i.v. injections of αCD137 + IL-2-Fc, Lipo-αCD137 + Lipo-IL-2-Fc, or Lipo-IgG on days 8, 10, and 12 post
tumor cell inoculation (100 μg per dose αCD137 and 60 μg per dose IL-2-Fc). On day 13, tumors and blood were processed to single cell suspensions for
ﬂow cytometry analysis. a Timeline of i.v. injections and ﬂow cytometry analysis. b, c The amounts of tumor-inﬁltrating CD8+ T-cells (b) and NK cells (c).
d The ratio of CD8+ T-cells and regulatory T-cells (Tregs) in tumors. *p< 0.05, **p< 0.005. e–g Lymphocytes from the tumors (e), TDLN (f), and blood
(g) were polyclonal stimulated in vitro. IFN-γ production by T-cells was analyzed by intracellular cytokine staining. **p< 0.005, *p< 0.05 vs. Untreated.
Lymphocytes from tumors were polyclonal stimulated in vitro with the presence of CD107a and CD107b antibodies. h Representative FACS plots and
statistical analysis of CD107 expressions on CD8+ T-cells in tumors. The production of granzyme B by CD8+ T lymphocytes was analyzed by intracellular
staining, as the indication of cytotoxic killing effect of activated T-cells by degranulation. *p< 0.05, **p< 0.01. i Representative ﬂow cytometry plots and
statistical analysis of granzyme B expressions in CD8+ T-cells in tumors. *p< 0.005, **p< 0.001. j, k Intracellular pSTAT5 activation in CD8 T-cells and NK
cells in tumor sites of primary melanoma (j) and lung metastatic melanoma (k) after the aforementioned treatments. Gray: untreated, blue: αCD137/IL2-
Fc, red: Lipo-αCD137/IL2-Fc, turquoise: Lipo-IgG. All measurements shown are mean± s.e.m.
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47/49/2/2 mol% was vacuum-dried in a glass vial and rehydrated in pre-warmed
PBS with vigorous vortexing for 1 min, followed by bath sonication at 50 °C for
5 min The resulting liposomes were pelleted by ultracentrifugation (Beckman
Coulter) at 40,000 r.p.m. for 4 h at 4 °C and the supernatant was removed. The
liposome pellet was resuspended in PBS prior to antibody/IL-2 conjugation.
IL-2-Fc is a bivalent protein of murine wild-type IL-2 linked to a mouse IgG2a
backbone and was produced as previously described11. A D265A mutation was
introduced in the IgG2a Fc region to minimize the interaction with Fc receptors on
phagocytes. To avoid opsonization by phagocytes, the Fc portion of anti-CD137
was digested by pepsin and cleaved by protein A using a Pierce F(Ab′)2 preparation
Kit before coupling to liposome surfaces. For experiments involving labeled pro-
teins, 10 µg Alexa Fluor dye 568 NHS Ester or IRDye 800CW NHS ester was added
to 100 µg anti-CD137 or IL-2-Fc (total concentration 2 mg/mL in 10 mM K2HPO4
pH 9) and mixed for 20 min, followed by washing away unreacted dye molecules
using a centrifugal ﬁlter unit with a 30 K MWCO membrane. For coupling IL-2-Fc
and anti-CD137 FAb2 proteins to maleimide-functionalize liposomes, antibody or
IL-2-Fc were reduced by 1.8 mM dithiothreitol (DTT) in the presence of 10 mM
EDTA for 20 min at 25 °C to expose free thiols in the IgG framework hinge region.
DTT was then removed by a centrifugal ﬁlter unit with 30 K MWCO membrane.
Fluorescently labeled antibodies were reduced in the same way. The reduced
anti-CD137, IL-2-Fc, or isotype control antibodies (ﬁnal concentration ~10 µg/µL)
were immediately added to maleimide-bearing liposomes (5 mg/mL lipids) in PBS
and allowed to react for 18 h at room temperature with continuous mixing.
β-mercaptoethanol (0.5 mM) was then added to block unreacted maleimide.
The resulting immunoliposomes were pelleted by ultracentrifugation and the
supernatant containing unreacted antibodies was removed. The pelleted antibody-
conjugated immunoliposomes were resuspended in PBS and stored at 4 °C
until use.
Hydrodynamic sizes and zeta potentials of immunoliposomes were measured
by DLS (Malvern Zetasizer Nano). Cryo-TEM was performed using a JEOL 2100F
transmission electron microscope. Fluorescently labeled antibodies were used in
the PK studies (Fig. 2d, e), biodistribution studies (Fig. 2f–i), confocal tissue
imaging (Fig. 3), and some ﬂow cytometry analysis (Fig. 2j), and allowed direct
determination of the amount of conjugated anti-CD137/IL-2-Fc. In experiments
where the cytokine/antibody payloads were not ﬂuorescently labeled, the antibody
loading was determined by an infrared spectroscopy protein assay, using a Direct
Detect infrared spectrometer (EMD Millipore).
For the immunoliposome in vitro stability assay, Alexa Fluor 488-labeled OVA
was encapsulated in liposome as a tracer of the liposome. Brieﬂy, 1.4 mg dried
lipids were hydrated in pre-warm PBS containing 46 µg Alexa Fluor 488-labeled
OVA with vigorous vortexing for 1 min and bath sonication at 50 °C for 5 min,
followed by manual extrusion through 0.1 µm pore size polycarbonate membrane.
The resulting liposomes were pelleted by ultracentrifugation at 50,000 rpm for 4 h
at 4 °C and the supernatant was removed. Anti-CD137 and IL-2-Fc were
conjugated with IRDye 800CW ﬂuorescent dye prior to coupling to OVA-loaded
liposomes. The ratios of anti-CD137 or IL-2-Fc to liposome (OVA ﬂuorescence)
over time were measured in vitro at 37 °C with continuous rotating, using PBS
containing 10% FBS as the release medium. At predetermined time points, the
release medium containing ﬂuorescence labeled immunoliposomes was subjected
to ultracentrifugation at 50,000 r.p.m. at 4 °C for 4 h. The resulting
immunoliposome pellet was disrupted by Triton X-100, and the ﬂuorescence
intensities of Alexa Fluor 488 and IRDye 800CW were measured by a ﬂuorescence
plate reader and LI-COR infrared spectroscopy instrument, respectively.
Normalized to the initial time point (set ratio as 1), the relative ratios of anti-
CD137 or IL-2-Fc to liposome ﬂuorescence were calculated.
Cell lines. B16F10 and A20 cells were from American Type Culture Collection
(ATCC), and B16F10-FLuc cell was made by transfection with a CMV promoter-
driven Fireﬂy luciferase reporter gene expression plasmid vector. The Trp2-KO
B16F10 cell line (B16F10-Trp2KO) was generated using CRISPR-Cas9 technology3.
B16F10, B16F10-FLuc, and B16F10-Trp2KO cells were cultured in DMEM (high
glucose) medium supplemented with 10% fetal bovine serum (FBS) and antibiotics
containing penicillin and streptomycin. A20 cells were cultured in RPMI-1640
medium supplemented with 10% FBS and antibiotics. Growth medium was
changed every 2–3 days.
Animals and tumor therapy. The experimental handling of mice was conducted
under federal, state, and local guidelines and following an approved protocol from
the Division of Comparative Medicine (DCM) of the Massachusetts Institute of
Technology. Except where otherwise noted, C57BL/6 mice (6–8-week-old female,
the Jackson laboratory) were subcutaneously inoculated with 5 × 105 B16F10 cells,
and treated on indicated days by i.v. injection of anti-CD137 and IL-2-Fc or other
combinations as noted. For the A20 B cell lymphoma model, female Balb/c mice
were subcutaneously inoculated with 2 × 106 A20 cells.
Lung metastases were established in C57BL/6 mice by i.v. injection of 5 × 105
B16F10-FLuc cells, which led to the formation of pulmonary metastatic tumor foci
in the lung. Tumors were traced following inoculation by bioluminescence
imaging. The total ﬂux obtained from bioluminescence imaging over a ﬁxed
thoracic area was used as a quantitative measurement of lung tumor burden.
Animals were treated by i.v. injection of αCD137/IL-2-Fc combinations as noted in
the text.
For subcutaneous tumors, tumor size was monitored every other day with
calipers, and areas were calculated as the product of orthogonal diameters of the
tumor. In the lung metastasis model, tumor burden was measured by
bioluminescence imaging with a Xenogen IVIS Spectrum Imaging System. Each
mouse received 150 mg luciferin/kg body weight subcutaneously 10 min before
imaging. Data was analyzed by Living Imaging Software. Body weight of the treated
mice were monitored as an indication of in vivo toxicity. Relative body weight was
normalized to the initial day of treatment. The physical condition and survival of
mice from each treatment group were monitored daily during the study.
In vitro T-cell binding and stimulation assays. Splenocytes from C57Bl/6 mice
were activated by conconavalin A (2 μg/mL) and IL-7 (1 ng/mL) for 2 days, and the
activated CD8+ T-cells were isolated using an EasySep Mouse CD8+ T-cell
enrichment Kit. To assess cellular binding, Alexa Fluor 555-conjugated Lipo-IL-2-
Fc, Lipo-αCD137, or Lipo-IgG were incubated with activated CD8+ T-cells for 3 h
at 37 °C, followed by analysis using ﬂow cytometry and confocal microscopy. For
bioactivity analysis, T-cells from C57BL/6 mice were activated by CD3/CD28 beads
(1:1 bead:cells ratio) for 2 days before the addition of IL-2-Fc or Lipo-IL-2-Fc (ﬁnal
IL-2 concentration 10 ng/mL). CD8+ T-cell and CD4+ T-cell counts were analyzed
by ﬂow cytometry on day 3 and day 4 post activation. Activated T-cells were
incubated with anti-CD137 or Lipo-αCD137 (ﬁnal anti-CD137 concentration 10
μg/mL) in the presence of 10 ng/mL recombinant murine IL-2 for 6 h, and the
secreted IFN-γ in the cell culture supernatant was analyzed by ELISA.
Pharmacokinetics study. Alexa Fluor647-conjugated Anti-CD137, IL-2-Fc, or
isotype control IgG were coupled to liposomes as described above. B16F10 tumor-
bearing mice were then given i.v. injections of the ﬂuorescently labeled anti-CD137,
Lipo-αCD137, IL-2-Fc, or Lipo-IL-2-Fc. At predetermined time points, 20 μL blood
from each mouse was collected via retro-orbital bleeding with a heparin-coated
capillary. The ﬂuorescence intensities in sera were measured by a Typhoon FLA
7000 ﬂuorescence spectrometer and the concentration of antibody was calculated
from a standard curve prepared for each reagent. The antibody concentrations in
sera were ﬁt to a bi-phasic exponential decay: MFI (t) =Ae−αt + Be−βt. Pharmaco-
kinetic parameters were calculated. t1/2,α, fast clearance half-life; t1/2,β, slow clear-
ance half-life; AUC, area under the curve.
Biodistribution analysis. IRDye 800CW infrared dye-conjugated anti-CD137, IL-
2-Fc, or isotype control IgG were coupled to liposomes as described above. B16F10
tumor-bearing mice then received i.v. injections of the infrared dye labeled anti-
CD137, Lipo-αCD137, IL-2-Fc, or Lipo-IL-2-Fc. Four hours and 24 hours later,
blood was drawn, and organs were collected and weighed. The ﬂuorescence
intensities in blood and all organs were measured by a LI-COR Odyssey imaging
system, and a percentage (%) of injected dose accumulated in organs was calculated
from predetermined standard curves, normalized by organ weights. For preparing
the standard curves, organs were dissected from mice and known doses (0, 0.0016,
0.008, 0.04, 0.2 µg) of IRDye CW800 infrared dye were injected into individual
organs before the ﬂuorescence intensities were measured using a LI-COR Odyssey
imaging system. The standard curve equations and R-squared (R2) values were
determined by Excel and GraphPad Prism software.
Luminex assay. Blood was collected from treated mice via retro-orbital bleeding
on indicated days and levels of inﬂammatory cytokines and chemokines (IFNγ, IL-
6, MCP-1, TNFα) in serum samples were determined by a Luminex assay using a
Luminex Milliplex Magnetic Bead Kit (EMD Millipore).
Lymphocyte depletions. B16F10 tumor-bearing mice were given intraperitoneal
(i.p.) injections of FTY720 at a dose of 3 mg/kg. One day later, mice were intra-
venously treated with anti-CD137 and IL-2-Fc, with 100 μg per dose of anti-CD137
and 60 μg per dose of IL-2-Fc. Animals subsequently received daily i.p. injections of
1 mg/kg FTY720 thereafter. One day and 3 days after anti-CD137/IL-2-Fc injec-
tion, peripheral blood was drawn and sera were collected. Cytokine and chemokine
levels in sera were measured by luminex cytokine assays as described above. For
NK cell and CD8+ T-cell depletion studies, B16F10 tumor-bearing mice were given
i.p. injections of 400 μg NK1.1 antibody, 400 µg CD8a antibody, or isotype control
antibody starting on day 6 post tumor cell inoculation, and the i.p. injections of
these depleting antibodies were given every 4 days till the end of the study. B16F10
tumor-bearing mice received i.v. injections of anti-CD137 and IL-2-Fc on days 8,
10, and 13 post tumor cell inoculation, with 100 μg per dose anti-CD137 and 60 μg
per dose IL-2-Fc.
Flow cytometry analysis. Mice bearing subcutaneous B16F10 melanomas were
given i.v. injections of anti-CD137 and IL-2-Fc, Lipo-αCD137/IL-2-Fc or Lipo-IgG
on days 8, 10, and 12 after tumor cell inoculation, with 100 μg per dose of αCD137
and 60 μg per dose of IL-2-Fc. Mice bearing B16F10-Fluc lung metastases were
given the same treatment and dosing on days 6, 8, and 10. One day after the third
injection, PBMC, TDLNs, tumors, or lungs were collected and processed to single
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cell suspension for antibody staining and ﬂow cytometry analysis on a BD
LSRFortessa Cell Analyzer. Regulatory T-cell (Treg) levels were quantiﬁed by
intracellular Foxp3 staining. Lungs were digested with collagenase IV and DNase
for 30 min at 37 °C to extract lymphocytes. Cells from PBMC, TDLNs, tumors, or
lungs were stimulated in vitro for 6 h with 12-myristate 13-acetate (PMA) (81 nM)
and ionomycin (1.34 µM) in the presence of brefeldin A (3 µg/mL) for 4 h to block
cytokine secretion. IFN-γ production by stimulated T-cells was measured by
intracellular cytokine staining, as an indicator of T-cell effector function. In par-
allel, lymphocytes from tumors were polyclonally stimulated in vitro by PMA and
ionomycin in the presence of CD107a and CD107b antibodies. One hour later,
menosin and brefeldin A were added to block cytokine secretion, and continuously
incubated for 4 h before antibody staining. The production of granzyme B by CD8+
T lymphocytes were analyzed by intracellular staining, as an indication of cytotoxic
killing effect of activated T-cells.
Immunohistochemistry analysis. Mice bearing subcutaneous B16F10 tumors
were administered i.v. injections of anti-CD137 and IL-2-Fc, Lipo-αCD137/IL-2-
Fc, or IL-2-Fc, Lipo-IL-2-Fc. One hour later, subcutaneous tumors were dissected
and immediately snap-frozen in dry ice with OCT cryo-embedding media for
cryosectioning. Ten micron tissue sections were cut for immunostaining proce-
dures as follows. The slides were ﬁxed twice in 100% ethanol for 30 min each time
before permeabilized with 0.2% Triton X-100 for 10 min The slides were blocked
with 5% goat serum for 1 h, followed by incubating with CD31 antibody (1:100)
and DAPI (1:2000) diluted in 1% goat serum for 2 h. Then slides were washed four
times with PBS before covering the slides with mounting medium. The images were
taken under an Olympus FV1200 Laser Scanning Confocal Microscope, with a ×30
magniﬁcation. The images and quantitative analysis were processed using ImageJ
software.
Vascular leak syndrome measurement. Mice bearing subcutaneous tumors were
given two i.v. injections of αCD137/IL-2-Fc and Lipo-αCD137/IL-2-Fc, at 100 μg
per dose anti-CD137 and 60 μg per dose IL-2-Fc. One day later, lungs were col-
lected and weighed before lyophilization. The lyophilized lungs were then weighed.
The water content (g) in the lung was calculated as: lung weight before lyophili-
zation (g)—lung weight after lyophilization (g).
Hematological test. Serum was isolated from mice 1 day after two treatments. The
liver enzymes AST and ALT, and cholesterol and creatinine kinase were analyzed
in the MIT Diagnostic lab, according to the manufacturer’s protocol and hospital
standards.
Statistical analysis. One-way analysis of variance was used to identify the dif-
ferences of measured continuous variables between groups. A two-tailed Student’s t
test will be used for the comparison between two groups with equal variance.
Survival analysis will be conducted using Kaplan–Meier curves and log-rank
(Mantel-Cox) test. Statistical signiﬁcance level will be deﬁned as P< 0.05.
Data availability. All relevant data are available from the authors on request and
are included with the manuscript and its supplementary information ﬁles.
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